We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
4SC Enters Next Phase of Drug Discovery Collaboration with SKK
News

4SC Enters Next Phase of Drug Discovery Collaboration with SKK

4SC Enters Next Phase of Drug Discovery Collaboration with SKK
News

4SC Enters Next Phase of Drug Discovery Collaboration with SKK

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "4SC Enters Next Phase of Drug Discovery Collaboration with SKK"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

4SC AG and Sanwa Kagaku Kenkyusho Co., Ltd. have announced that they have achieved the first milestone and entered the next phase of their drug discovery collaboration which was started in January 2005.

To date 4SC has applied its proprietary virtual High Throughput Screening technology, 4SCan® to identify active agents against specific targets provided by SKK, followed by corresponding biological screening experiments. 

A dedicated team of 4SC scientists shall now further optimize hits and leads with respect to certain properties like potency, selectivity and their in vitro ADMET profile.

The achievement of the first milestone triggers an undisclosed payment from SKK as well as the continuation of the partnership.

"We are extremely pleased with the quality and speed of the results achieved by 4SC," commented Mr. Satoshi Terao, SKK's Vice President for Research and Development. 

"In the last months we have built an excellent relationship and we are looking forward to a continued fruitful collaboration."

"We are very proud that we have reached our first project milestone with SKK," stated Dr Daniel Vitt, CSO of 4SC.

"This success is yet another validation of the efficiency of our drug discovery platform and demonstrates the added value we can offer our partners within the biopharmaceutical industry worldwide."

Advertisement